Project | SCLC | NSCLC | P Value | LADC | LSCC | P Value |
---|---|---|---|---|---|---|
Before treatment | ||||||
CEA (ng/ml) | 96.73 ± 9.11 | 96.01 ± 9.31 | 0.65 | 95.54 ± 9.78 | 95.82 ± 9.12 | 0.86 |
NSE (ng/ml) | 88.71 ± 7.43 | 88.61 ± 7.51 | 0.94 | 88.63 ± 7.49 | 88.59 ± 7.49 | 0.97 |
CYFRA21-1 (ng/ml) | 37.87 ± 5.87 | 37.84 ± 5.90 | 0.98 | 37.82 ± 5.88 | 37.85 ± 5.89 | 0.96 |
CA199 U/ml | 51.78 ± 7.48 | 51.84 ± 7.52 | 0.96 | 51.82 ± 7.52 | 51.85 ± 7.51 | 0.98 |
After treatment | ||||||
CEA (ng/ml) | 24.66 ± 1.55 | 20.25 ± 1.1 | < 0.0001 | 20.27 ± 1.08 | 20.24 ± 1.09 | 0.87 |
NSE (ng/ml) | 28.15 ± 1.97 | 22.81 ± 1.75 | < 0.0001 | 22.83 ± 1.73 | 22.79 ± 1.73 | 0.89 |
CYFRA21-1 (ng/ml) | 10.13 ± 0.13 | 9.55 ± 0.22 | < 0.0001 | 9.54 ± 0.21 | 9.57 ± 0.2 | 0.38 |
CA199 U/ml | 29.22 ± 2.62 | 24.16 ± 1.7 | < 0.0001 | 24.14 ± 1.72 | 24.17 ± 1.71 | 0.92 |